Resources Contact Us Home
Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodies

Image Number 12 for United States Patent #7491393.

The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

  Recently Added Patents
Exposure apparatus, exposure method, and device manufacturing method
Evaluation compiler method
Remotely provisioned wireless proxy
Wire guide
Gate timing for short servo wedge in disk memory systems
Systems, computer programs, and methods for controlling costs of a healthcare practice
  Randomly Featured Patents
Power and information signal transfer using micro-transformers
NROM fabrication method
Acousto-optic frequency shifter using optical fiber and method of manufacturing same
Switchable optical components
Bellows container
Benzoxazepine compounds, their production and use as lipid lowering agents
Secondary combustion system for woodburning stove
Method of manufacturing laminated core for dynamo-electric machine
Commercial LED fixture with main reflector having a pair of oppositely disposed wall washes
Cosmetic bottle